Celularity (CELU) vs Citius Pharmaceuticals (CTXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed Celularity (CELU) over the past year, losing 55.4% versus a loss of 73.5%. Over five years, CTXR leads with a -98.8% price change compared with -99.3% for CELU. Celularity is the larger company by market cap ($15.0 million vs $14.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | CTXR |
|---|---|---|
| Share price | $0.463 | $0.5085 |
| Market cap | $15.02M | $13.96M |
| 1-day change | -1.05% | +2.27% |
| YTD return | -58.29% | -34.56% |
| 1-year return | -73.54% | -55.39% |
| 5-year return | -99.31% | -98.79% |
| EPS (TTM) | $-1.69 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $26.55M | — |
| Revenue growth (YoY) | -51.03% | — |
| Net income (latest FY) | $-91.72M | $-39.74M |
| Gross margin | 24.39% | — |
| Operating margin | -230.92% | — |
| Net margin | -345.45% | — |
| 52-week high | $2.55 | $1.54 |
| 52-week low | $0.42 | $0.37 |
| Distance from 52-week high | -81.84% | -66.98% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +686.63% |
| Average volume | 3.95M | 275.44K |
| Shares outstanding | 32.45M | 27.45M |
| Employees | 115 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed CELU by 18.1 percentage points over the past year.
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
CELU vs CTXR FAQ
Which is bigger, Celularity or Citius Pharmaceuticals?
Celularity (CELU) is larger, with a market capitalization of $15.02M compared with $13.96M for Citius Pharmaceuticals (CTXR).
Which stock has performed better over the past year, CELU or CTXR?
CTXR returned -55.39% over the past 12 months, compared with -73.54% for CELU (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and Citius Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.